Octarine Bio adds EUR 5 million funding, bringing their Series A total to EUR 12.8 million

The Danish BioTech company has completed a Series A financing round, led by existing investors as well as new partners, including The Footprint Firm, Unconventional Ventures, Edaphon, DSM-Firmenich Ventures, Oskare Capital, and several business angels. The additional EUR 5 million in funding brings its total Series A raise to EUR 12.8 million.

Founded in 2018, Octarine Bio is a world-leading synthetic biology platform, built on scientific expertise in cell factory engineering, precision fermentation, and enzymatic enhancement.

The investment will help accelerate industrial-scale validation and enable the commercial launch of Octarine Bio’s precision-fermented pigment platform, PurePalette, supporting its adoption across various industries, including food and fashion.

Mazanti Transactions advised Octarine Bio in connection with all aspects of the investment.